49
Participants
Start Date
April 9, 2018
Primary Completion Date
October 5, 2018
Study Completion Date
October 5, 2018
BIA 5-1058
"Subjects will receive BIA 5-1058 tablets (containing 100 mg) as single, oral doses 30 minutes after the start of a moderate mealas follows:~* 400 mg BIA 5 1058, as 4 × 100 mg tablets and 8 placebo tablets~* 1200 mg BIA 5 1058, as 12 × 100 mg tablets"
Placebo Oral Tablet
"Matching placebo tablets administered as follows:~\- placebo, as 12 × 0-mg tablets"
Moxifloxacin 400 mg
"Administered as follows:~\- 400 mg moxifloxacin, as 1 × 400-mg tablet"
Covance Clinical Research Unit Ltd., Leeds
Collaborators (1)
Covance
INDUSTRY
Bial - Portela C S.A.
INDUSTRY